1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Suvorexant
Trade Name:
Belsomra
Manufacturer/Distributor:
Merck Canada Inc.
merck.ca
Classification:
Hypnotic
ATC Class:
N05CM19 - suvorexant
Status:
active
Notice of Compliance (yyyy/mm/dd):
2018/11/29
Date Marketed in Canada (yyyy/mm/dd):
2019/04/16
Presentation:
Tablet: 10 mg. DIN: 02483513
Tablet: 15 mg. DIN: 02483521
Tablet: 20 mg. DIN: 02483548
Comments:
For treatment of insomnia. It is an orexin receptor antagonist. The orexin neuropeptide signaling system is a central promoter of wakefulness. Orexin producing neuronal cell bodies are localized specifically in the hypothalamus and project to the wakefulness mediating neurons of the brain. Suvorexant is thought to suppress wake drive by blocking the binding of the wake-promoting neuropeptides orexin A and orexin B to OX1R and OX2R reversibly.
Source:
Product mongoraph
Back to:
Drug Product Listings 
